Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of HAE-1/HAE-2 (for inclusion in Part A) or HAE-nC1-INH (for inclusion in Part B)~* Participants must have experienced a minimum of 2 HAE attacks (assessed by the Angioedema Activity Score \[AAS\] and confirmed by the investigator) during the screening period~* Access to, and the ability to use, ≥ 1 acute medication(s) to treat angioedema attacks~Exclusion Criteria:~* Anticipated use of short-term prophylaxis for angioedema attacks for a pre-planned procedure during the screening or study periods~* Concurrent diagnosis of any other type of recurrent angioedema, including acquired or idiopathic angioedema~* Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C, or chronic hepatitis B~* Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated~* Treatment with another investigational drug or biological agent within 1 month or 5 half-lives, whichever is longer, of screening~* Exposure to any of the following medications:~  * Angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing medications with systemic absorption (such as oral contraceptive or hormonal replacement therapy) within 4 weeks prior to screening~ * Chronic prophylaxis with Lanadelumab within 10 weeks prior to screening~ * Oligonucleotides (including small interfering ribonucleic acid \[RNA\]) within 4 months of screening (if single dose received) or within 12 months of screening (if multiple doses received)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A: Placebo (Type: PLACEBO_COMPARATOR): Participants with hereditary angioedema type I/type II (HAE-1/HAE-2) received placebo subcutaneously (SC) every 4 weeks at Weeks 1, 5, 9, and 13.
- Part A: Donidalorsen 80 mg (Type: EXPERIMENTAL): Participants with HAE-1/HAE-2 received donidalorsen, 80 mg, SC, every 4 weeks at Weeks 1, 5, 9, and 13.
- Part B: Donidalorsen 80 mg (Type: EXPERIMENTAL): Participants with hereditary angioedema with normal C1-inhibitor (HAE-nC1-INH) received donidalorsen, 80 mg, SC, every 4 weeks at Weeks 1, 5, 9, and 13.

Based on this trial design, predict the completion outcome and termination type (if applicable).